With shares of Microsoft (NASDAQ:MSFT) trading around $37, is MSFT an OUTPERFORM, WAIT AND SEE, or STAY AWAY? Let�� analyze the stock with the relevant sections of our CHEAT SHEET investing framework:
T = Trends for a Stock’s MovementMicrosoft is engaged in developing, licensing, and supporting a wide range of software products and services. The company also designs and sells hardware and delivers online advertising to customers. It operates in five segments: Windows and Windows Live, Server and Tools, Online Services Division, Microsoft Business Division, and Entertainment and Devices. As a mature company, Microsoft is also offering a stable dividend, which is currently yielding around 3.32 percent annually.
Microsoft ended its recent business day with the advanced of 0.97 percent and closed at the price of $37.44 after opening at $37.20. The stock traded during its last trading session with the total volume of 17.61 million shares, as compared to its average volume of 40.94 million shares.
Top 5 Gas Companies To Buy Right Now: Cabot Microelectronics Corporation(CCMP)
Cabot Microelectronics Corporation engages in the development, manufacture, and sale of chemical mechanical planarization (CMP) consumables to the semiconductor industry primarily in the United States, Asia, and Europe. CMP is a polishing process used by integrated circuit (IC) device manufacturers to planarize or flatten the multiple layers of material that are deposited upon silicon wafers in the production of advanced ICs. The company offers CMP slurries, which are liquid solutions composed of high-purity deionized water, proprietary chemical additives, and engineered abrasives that chemically and mechanically interact with the surface material of the IC device at an atomic level; and CMP polishing pads that are engineered polymeric materials designed to distribute and transport the slurry to the surface of the wafer and distribute it evenly across the wafer. Its CMP slurries are used for various polishing applications, including materials that conduct electrical signal s, such as tungsten, copper, tantalum, and aluminum; the dielectric insulating materials that separate conductive layers within logic and memory IC devices; and the disk substrates and magnetic heads used in hard disk drives. The company also designs and produces precision polishing and metrology systems to attain shape and surface finish on various optical components, such as mirrors, lenses, and prisms. It serves producers of logic IC devices and memory IC devices, as well as IC foundries. The company was founded in 1999 and is headquartered in Aurora, Illinois.
Advisors' Opinion:- [By Nikolaj Gammeltoft]
Not all of Granville�� best calls were in the distant past. On March 11, 2000, the day after the Nasdaq Composite Index (CCMP) jumped to a record 5048.62, Granville wrote that investors in technology stocks ��ill soon be burned.��The index, heavy on computer-related companies, tumbled about 78 percent before bottoming on Oct. 9, 2002.
Best Sliver Stocks To Own For 2014: Brookline Bancorp Inc.(BRKL)
Brookline Bancorp, Inc. operates as the holding company for Brookline Bank, Bank Rhode Island, and The First National Bank of Ipswich, which provide commercial and retail banking services, and cash management and investment services to customers in Central New England. The company accepts various deposit products, including non-interest-bearing checking accounts, interest-bearing NOW accounts, savings accounts and money market savings accounts, certificate of deposit accounts, individual retirement accounts, and other qualified plan accounts. Its loan portfolio comprises first mortgage loans secured by commercial, multi-family, and residential real estate properties; auto loans; loans to business entities consisting of commercial lines of credit; and loans to condominium associations, as well as loans for financing equipment used by small businesses. Brookline Bancorp, Inc. also provides financing for construction and development projects, home equity, and other consumer l oans; and loans to finance coin-operated laundry, dry cleaning, and convenience store equipment and businesses. As of January 25, 2012, it operated 43 branches in Massachusetts and Rhode Island. The company was founded in 1871 and is headquartered in Brookline, Massachusetts.
Advisors' Opinion:- [By CRWE]
Brookline Bancorp, Inc. (NASDAQ:BRKL) announced today that it will report third quarter earnings 2012 at the close of business Wednesday, October 24, 2012. Management will host a conference call to review this information at 1:30 PM Eastern Time on Thursday, October 25, 2012.
- [By Dividends4Life]
Memberships and Peers: PBCT is a member of the S&P 500 and a member of the Broad Dividend Achievers��Index. The company's peer group includes: Bank of America Corporation (BAC) with a 0.3% yield, Brookline Bancorp, Inc. (BRKL) with a 3.7% yield and Westfield Financial Inc. (WFD) with a 3.5% yield.
Best Sliver Stocks To Own For 2014: Centene Corporation (CNC)
Centene Corporation provides multi-line healthcare programs and services in the United States. It operates in two segments, Medicaid Managed Care and Specialty Services. The Medicaid Managed Care segment provides Medicaid and Medicaid-related health plan coverage to individuals through government subsidized programs, including Medicaid, the State children�s health insurance program, long-term care, foster care, and Medicare special needs plans, as well as aged, blind, or disabled programs. Its health plans provide primary and specialty physician care, inpatient and outpatient hospital care, transportation assistance, emergency and urgent care, vision care, prenatal care, dental care, laboratory and x-ray services, immunizations, prescriptions and over-the-counter drugs, home health and durable medical equipment, behavioral health and substance abuse services, therapies, social work services, care coordination, and 24-hour nurse advice line. The Specialty Services segment manages behavioral healthcare for members; provides health insurance to individual customers and their families; implements life and health management programs; offers long-term care services to the elderly and people with disabilities; and administers routine and medical surgical eye care benefits through its network of eye care providers. It also offers telehealth services; and claims processing, pharmacy network management, benefit design consultation, drug utilization review, formulary and rebate management, specialty and mail order pharmacy services, and patient and physician intervention services, as well as provides care management solutions that automate the clinical, administrative, and technical components of care management programs. The company offers its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.
Advisors' Opinion:- [By Monica Gerson]
Centene (NYSE: CNC) is estimated to report its Q3 earnings at $0.84 per share on revenue of $2.68 billion.
FMC Technologies (NYSE: FTI) is projected to post its Q3 earnings at $0.59 per share on revenue of $1.75 billion.
- [By Holly LaFon]
Importantly, we like the industry in which Centene (CNC) competes. Some of our investors might recall that one of our prior investments, Amerigroup, was acquired in 2012 by Wellpoint at a val uation that allowed us to achieve a return on investment of greater than 100% over the roughly one - year time period that we owned the shares. Medicaid managed care companies not only save states money but also offer better service; therefore, more states a re letting managed care companies run their Medicaid programs. To that end, states are expanding both the geographies carved out to managed care companies and the types of programs. The next phase of growth will come from the dual - eligible population. D uals (or dual - eligible population) are 8.3mm 3 people in the U.S. that are eligible to receive both Medicare and Medicaid benefits (mainly low - income seniors). According to the Kaiser Foundation, Duals accounted for almost 40% of Medicaid spending although they made up only 15% of the Medicaid population. We believe there are ample growth opportunities for CNC and other companies to meet the challenges of managing these disparate Medicaid members for the foreseeable future.
- [By Jake L'Ecuyer]
Shares of Centene (NYSE: CNC) got a boost, shooting up 9.77 percent to $62.89 on upbeat quarterly results. Centene reported its Q1 earnings of $0.57 per share on revenue of $3.46 billion.
- [By Lauren Pollock]
Centene Corp.(CNC) agreed to acquire a roughly 68% interest in U.S. Medical Management LLC, a provider of in-home health services, for $200 million in cash and stock as the Medicaid insurer continues to expand its stable of services. Centene also said it is forming a new health-care enterprise holding company that will connect it and other health solution providers.
Best Sliver Stocks To Own For 2014: Shire PLC (SHPG)
Shire plc (Shire), incorporated on January 28, 2008, is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), gastrointestinal (GI) diseases, human genetic therapies (HGT) and regenerative medicine (RM), as well as opportunities in other therapeutic areas. As of December 31, 2012, the Company�� products included VYVANSE/VENVANSE (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), EQUASYM (methylphenidate hydrochloride) modified release (XL), LIALDA (mesalamine)/ MEZAVANT(mesalazine), PENTASA (mesalamine), RESOLOR (prucalopride), FOSRENOL (lanthanum carbonate), XAGRID (anagrelide hydrochloride), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant) and DERMAGRAFT(Human Fibroblast-Derived Dermal Substitute). As of December 31, 2012, the Company�� products under development included INTUNIV (extended release guanfacine), VYVANSE/VENVANSE (lisdexamfetamine dimesylate), INTUNIV, Guanfacine Carrier Wave, LIALDA (mesalamine)/MEZAVANT (mesalazine), RESOLOR (prucalopride), RESOLOR (prucalopride), SPD 557(M0003), XAGRID, VYVANSE (lisdexamfetamine dimesylate), REPLAGAL (agalsidase alfa), HGT-4510, HGT-2310, HGT-1410, HGT-1110, HGT-3010, and DERMAGRAFT. On January 31, 2012, the United States Food and Drug Administration approved VYVANSE for the maintenance treatment of ADHD in adults. In March 2013, it announced the acquisition Of Premacure AB. In January 2014, Shire Plc sold its DERMAGRAFT assets to Organogenesis Inc. In January 2014, Shire Plc acquired 79.5% interest in ViroPharma Inc.
VANSE/ VENVANSE
VYVANSE is a New Chemical Entity (NCE) and is the pro-drug stimulant for the treatment of ADHD, where the amino acid l-lysine is linked to d-amphetamine. VYVANSE is therapeutically inactive until metabolized in the body. The United Stat! es Food and Drug Administration approved VYVANSE as a once-daily treatment for children aged 6 to 12 with ADHD in February 2007, for adults in April 2008 and for adolescents aged 13 to 17 in November 2010. VYVANSE is available in the United States in six dosage strengths: 20 milligram, 30 milligram, 40 milligram, 50 milligram, 60 milligram and 70 milligram. Health Canada approved VYVANSE for the treatment of ADHD in pediatric patients aged 6 to 12 in February 2009, and for adolescents and adults in November 2010. In April 2012, ANVISA, the Brazilian health authority, granted marketing authorization approval for lisdexamfetamine dimesylate for the treatment of ADHD in children aged 6-12.
ADDERALL XR
ADDERALL XR is an extended release treatment for ADHD, which uses MICROTROL drug delivery technology and is designed to provide once-daily dosing. It is available in 5 milligram, 10 milligram, 15 milligram, 20 milligram, 25 milligram and 30 milligram capsules and can be administered either as a capsule or sprinkled on soft food. The United States Food and Drug Administration has approved ADDERALL XR as a once-daily treatment for children aged 6 to 12 with ADHD, for adults in and for adolescents aged 13 to 17. Teva Pharmaceutical Industries, Ltd. (Teva) and Impax Laboratories, Inc. (Impax) commenced commercial shipment of their authorized generic versions of ADDERALL XR in April and October 2009, respectively. Shire receives royalties from Impax�� sales of authorized generic ADDERALL XR.
INTUNIV
INTUNIV is a selective alpha-2A receptor agonist indicated for the treatment of ADHD. Alpha-2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signalling in the prefrontal cortex (Cell. 2007; 129:397-410). INTUNIV is non-scheduled and has no known potential for abuse or dependence. The United States Food and Drug Administration approved INTUNIV in September 2009, as a once-daily monotherapy treatment of ADHD in children and adolesce! nts aged ! 6 to 17. It is available in 1 milligram, 2 milligram, 3 milligram and 4 milligram tablets.
EQUASYM
Shire has acquired from UCB the worldwide rights (excluding the United States, Canada and Barbados) to EQUASYM (methylphenidate hydrochloride) IR and XL for the treatment of ADHD in children and adolescents aged 6 to 18. At December 31, 2012,EQUASYM XL was commercially available in 10 countries in 10mg, 20mg and 30mg strengths. EQUASYM XL is marketed in Mexico and South Korea under the trade name METADATE CD.
LIALDA/MEZAVANT
LIALDA is indicated for the induction ofmild to moderately active UC and for the maintenance of remission of UC. The addition of the indication for maintenance of remission of ulcerative colitis was approved by Health Canada in February 2011, and by the United States Food and Drug Administration in July 2011. LIALDA is once-daily oral formulation of mesalamine indicated for the induction and maintenance of remission. As of December 31, 2012, LIALDA/MEZAVANT (this product is marketed outside the United States as MEZAVANT) was commercially available in 19 countries either directly or through distributor arrangements.
PENTASA
PENTASA controlled release capsules are approved in the United States (marketed by Shire in the United States and by Ferring outside of the United States) and indicated for the induction of remission and for the treatment of patients with mild to moderately active ulcerative colitis. PENTASA is an ethylcellulose-coated, controlled release capsule formulation designed to release therapeutic quantities of mesalamine throughout the gastrointestinal tract. PENTASA is available in the United States in 250 milligram and 500 milligram capsules.
RESOLOR
RESOLOR (prucalopride), a 5-HT4 receptor agonists that stimulates gastrointestinal motility and acts primarily on different parts of the lower gastrointestinal tract (enterokinetic). In October 2009, RESOLOR was appr! oved by t! he EMA throughout the European Union as a once daily oral treatment for symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief. In July 2010, Swissmedic granted RESOLOR marketing authorization in Switzerland for the treatment of idiopathic chronic constipation in adults. RESOLOR is available in milligram and 2 milligram dose strengths, both for once-daily dosing. At December 31, 2012, RESOLOR was available in six European Union countries. Formulated as a chewable tablet, FOSRENOL is available in 500 milligram, 750 milligram and 1,000 milligram dosage strengths.
XAGRID
XAGRID (anagrelide hydrochloride) is marketed in Europe for the reduction of elevated platelet counts in at-risk ET patients. XAGRID has been granted orphan drug status in the European Union. In the United States, anagrelide hydrochloride is sold by the Company under the name AGRYLIN for the treatment of thrombocythemia secondary to a MPD.
REPLAGAL
REPLAGAL is for the treatment of Fabry disease. Fabry disease is a genetic disorder resulting from a deficiency in the activity of the lysosomal enzyme alpha-galactosidase A, which is involved in the breakdown of fats. REPLAGAL is a human alpha-galactosidase A protein made in human cells that replaces the deficient alpha-galactosidase A with an active enzyme to ameliorate certain clinical manifestations of Fabry disease. At December 31, 2012, REPLAGAL was approved in 46 countries.
ELAPRASE
ELAPRASE is a treatment for Hunter syndrome (also known as Mucopolysaccharidosis Type II or MPS II). Hunter syndrome is a genetic disorder mainly affecting males that interferes with the body's ability to break down and recycle waste substances called mucopolysaccharides, also known as glycosaminoglycans (GAGs). ELAPRASE was approved by the United States Food and Drug Administration and granted marketing authorization by the EMA for the long term treatment of patients with Hunter ! syndrome.! ELAPRASE has been granted orphan drug by both the United States Food and Drug Administration and the EMA. ELAPRASE received approval from the Ministry of Health, Labour and Welfare in Japan. At December 31, 2012, ELAPRASE was approved in 51 countries.
VPRIV
VPRIV is a treatment for Type 1 Gaucher disease. Gaucher disease is an inherited genetic disorder, which results in a deficiency of the lysosomal enzyme beta-glucocerebrosidase. VPRIV was approved by the United States Food and Drug Administration in February 2010, for the long-term treatment of patients with Type 1 Gaucher disease. The EMA approved the marketing authorization for the use of VPRIV in August 2010. VPRIV was authorized as an orphan medicine through the Centralised Procedure in Europe. At December 31, 2012, VPRIV was approved in 38 countries.
FIRAZYR
FIRAZYR is a peptide-based therapeutic developed for the symptomatic treatment of acute attacks of HAE. In July 2008 the EMA granted marketing authorization throughout the European Union for the use of FIRAZYR for the symptomatic treatment of acute attacks of HAE, and in May 2011 approved FIRAZYR for self-administration after training in subcutaneous injection technique by a healthcare professional. In August 2011, the United States Food and Drug Administration granted marketing approval for FIRAZYR in the United States for treatment of acute attacks of HAE in adults aged 18 and older. After injection training, patients may self-administer FIRAZYR. FIRAZYR has been granted orphan drug by both the United States Food and Drug Administration and the EMA. At December 31, 2012, FIRAZYR was approved in 38 countries globally.
DERMAGRAFT
DERMAGRAFT is a bio-engineered skin substitute that assists in restoring damaged tissue. DERMAGRAFT is indicated for use in the treatment of full-thickness Diabetic foot ulcers (DFU) greater than six weeks in duration, which extend through the dermis, but without tendon, muscle, joint capsu! le, or bo! ne exposure. DERMAGRAFT is approved by the United States Food and Drug Administration as a Class III medical device for the treatment of DFUs. DERMAGRAFT is also approved for the treatment of DFUs in South Africa, Israel and Singapore.
The Company competes with Shionogi & Co., Ltd., Janssen-Cilag, Novartis, Medice, Eli Lilly, Warner Chilcott, Synergy Pharmaceuticals, Inc., ARYx Therapeutics, Theravance, Inc., Sucampo Pharmaceuticals, Inc., Albireo, Actelion Ltd., Protalix BioTherapeutics Inc, Genzyme, CSL Behring, Pharming Group N.V., ViroPharma, Dyax Corporation, Organogenesis, Healthpoint, Soluble System, KCI, Smith & Nephew, Aurobindo and Apotex.
Advisors' Opinion:- [By Anna Prior]
U.S. drug giant Abbvie is close to clinching a deal to buy Dublin-based Shire (SHPG) PLC for more than $53 billion, in what would be one of the largest so-called inversion deals through which U.S. companies are seeking a lower corporate tax burden. Shire American depositary shares rose 1.7% to $253.17, while Abbvie shares slipped 2.7% to $53.50 premarket.
No comments:
Post a Comment